| 1 |
34703007 | Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. | 2022 Mar |
2 |
| 2 |
34968866 | Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan. | 2022 Feb |
1 |
| 3 |
34917992 | Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report. | 2021 Dec |
1 |
| 4 |
31889589 | Cetuximab enhances the efficiency of irinotecan through simultaneously inhibiting the MAPK signaling and ABCG2 in colorectal cancer cells. | 2020 Feb |
1 |
| 5 |
32993166 | Injectable Thermo-Sensitive Chitosan Hydrogel Containing CPT-11-Loaded EGFR-Targeted Graphene Oxide and SLP2 shRNA for Localized Drug/Gene Delivery in Glioblastoma Therapy. | 2020 Sep 26 |
6 |
| 6 |
30662270 | Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report. | 2019 |
2 |
| 7 |
30733972 | A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan. | 2019 |
1 |
| 8 |
29760556 | Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer. | 2018 |
3 |
| 9 |
27060453 | Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38. | 2017 Feb |
2 |
| 10 |
28025786 | EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. | 2017 Jul |
1 |
| 11 |
28220486 | Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada. | 2017 May 1 |
2 |
| 12 |
28439659 | Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan. | 2017 Jun |
1 |
| 13 |
28695301 | Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. | 2017 Jun |
1 |
| 14 |
26381420 | N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. | 2016 Feb |
1 |
| 15 |
27091477 | Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report. | 2016 Apr 18 |
1 |
| 16 |
27246726 | ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. | 2016 May 31 |
1 |
| 17 |
27340349 | Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. | 2016 Jun 21 |
2 |
| 18 |
27729313 | Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. | 2016 Dec |
1 |
| 19 |
26275292 | Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. | 2015 |
1 |
| 20 |
26461062 | Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. | 2015 Nov 3 |
1 |
| 21 |
26504021 | Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion. | 2015 Nov |
2 |
| 22 |
23821377 | EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. | 2014 Sep |
5 |
| 23 |
24513691 | Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. | 2014 Aug |
2 |
| 24 |
24968756 | Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). | 2014 |
1 |
| 25 |
25369798 | Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. | 2014 Nov 5 |
1 |
| 26 |
22973964 | Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. | 2013 |
6 |
| 27 |
23555046 | Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model. | 2013 |
1 |
| 28 |
23960095 | Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. | 2013 Oct |
1 |
| 29 |
27121781 | Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer. | 2013 Jul |
2 |
| 30 |
21706149 | Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. | 2012 Aug |
2 |
| 31 |
22112971 | Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. | 2012 Jul |
1 |
| 32 |
22192364 | Treatment decisions after diagnosis of metastatic colorectal cancer. | 2012 Sep |
1 |
| 33 |
23176042 | Current status of radiosensitizing agents for the management of rectal cancer. | 2012 |
1 |
| 34 |
25436684 | Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells. | 2012 Jun |
1 |
| 35 |
21286718 | Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan. | 2011 Oct |
6 |
| 36 |
21439039 | EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. | 2011 Mar 25 |
1 |
| 37 |
21559018 | Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. | 2011 May 24 |
1 |
| 38 |
21997136 | An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells. | 2011 Nov 8 |
6 |
| 39 |
19862647 | MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. | 2010 Dec |
1 |
| 40 |
20067946 | The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. | 2010 |
2 |
| 41 |
20666740 | Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. | 2010 Aug |
1 |
| 42 |
21036743 | Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). | 2010 Oct |
1 |
| 43 |
21208842 | Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. | 2010 Dec |
2 |
| 44 |
19151561 | [Lung cancer]. | 2009 Jan |
3 |
| 45 |
19534437 | [Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute]. | 2009 |
1 |
| 46 |
19581859 | Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin. | 2009 Jun |
2 |
| 47 |
19671328 | [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation]. | 2009 May 26 |
1 |
| 48 |
19738126 | Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. | 2009 Oct 20 |
3 |
| 49 |
19915942 | Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. | 2009 Dec |
1 |
| 50 |
19917537 | Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. | 2009 Nov |
1 |